Complexin 2 is a protein modulator of neurotransmitter release that is downregulated in humans suffering from depression, animal models of depression and neurological disorders such as Huntington's disease in which depression is a major symptom. Although complexin 2 knockout (Cplx2 2/ 2 ) mice are overtly normal, they show significant abnormalities in cognitive function and synaptic plasticity. Here we show that Cplx2 2/2 mice also have disturbances in emotional behaviours that include abnormal social interactions and depressive-like behaviour. Since neurotransmitter deficiencies are thought to underlie depression, we examined neurotransmitter levels in Cplx2 2/2 mice and found a significant decrease in levels of noradrenaline and the serotonin metabolite 5-hydroxyindoleacetic acid in the hippocampus. Chronic treatment with clorgyline, an irreversible inhibitor of monoamine oxidase A, restored hippocampal noradrenaline to normal levels (from 60 to 97% of vehicle-treated Cplx2 1/1 mice, P < 0.001), and reversed the behavioural deficits seen in Cplx2 2/ 2 mice. For example, clorgyline-treated Cplx2 2/2 mice spent significantly more time interacting with a novel visitor mouse compared with vehicle-treated Cplx2 2/2 mice in the social recognition test (34 compared with 13%, P < 0.01). We were also able to reverse the selective deficit seen in mossy fibrelong-term potentiation (MF-LTP) in Cplx2 2/2 mice using the noradrenergic agonist isoprenaline. Pre-treatment with isoprenaline in vitro increased MF-LTP by 125% (P < 0.001), thus restoring it to control levels. Our data strongly support the idea that complexin 2 is a key player in normal neurological function, and that downregulation of complexin 2 could lead to changes in neurotransmitter release sufficient to cause significant behavioural abnormalities such as depression.
INTRODUCTION
Complexins are small, cytosolic proteins that bind to the soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) complex to regulate synaptic vesicle exocytosis (1, 2) . Complexin 1 and 2 are the two major isoforms in the brain (1) . From functional analyses using complexin knockout mice, it was concluded that complexins operate at a post-priming step in synaptic vesicle excocytosis by stabilizing SNARE complexes in a highly fusogenic 'super-primed' state (3, 4) . In contrast, studies on neuromuscular junctions of Drosophila complexin null mutants (5) and in other in vitro systems (6) (7) (8) (9) revealed that complexin acts as a clamp that arrests SNARE complexes until the appropriate calcium signal is provided. Recent approaches using crossspecies rescue experiments showed that murine and Drosophila complexins have both facilitatory and inhibitory functions associated with similar protein domains in synaptic vesicle exocytosis (10) .
Significant alterations of complexins I and II expression levels are seen in a number of neurological and psychiatric disorders, including bipolar disorder (11) (12) (13) , major depression (12, 14) , Huntington's disease (HD) (15, 16) , schizophrenia * To whom correspondence should be addressed. Tel: +44 1223334057; Fax: +44 1223334100; Email: ajm41@cam.ac.uk # The Author 2010. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org (11, 14, (17) (18) (19) (20) (21) ), Parkinson's disease (22) and Alzheimer's disease (23) . Changes in complexins have also been seen in animal or cell culture models of depression (24) , HD (25) (26) (27) and Parkinson's disease (28) . However, it is not clear whether complexin dysregulation plays a direct role in the aetiology of the disorders in which they have been implicated and contributes to the symptoms, or if they are compensatory.
The importance of complexins is unequivocal since double knockout mice die at birth (3). The two major isoforms of complexin are differentially and reciprocally distributed in the brain (29, 30) . The highest expression levels of Cplx1 are seen in the cortex, thalamus and deep cerebellar nuclei. In contrast, Cplx2 had highest expression in the striatum, hippocampus, amygdaloid nuclei and cortex.
As might be expected from their expression patterns, the behavioural phenotypes of the single knockouts are very different. Cplx 1 knockout (Cplx1 2/2 ) mice exhibit early neurological symptoms characterized by a profound ataxia (present from postnatal day 7 and represents the earliest known ataxia in a mouse model; 31, 32) . In addition to their pronounced locomotor deficits, Cplx1 2/2 mice also have deficits in many aspects of social behaviour and tasks reflecting emotional reactivity, although they appear to have normal cognitive function (33) . In contrast, adult Cplx2 knockout (Cplx2 2/2 ) mice appear outwardly normal. Although their behavioural abnormalities are effectively 'hidden', comprehensive behavioural testing revealed subtle underlying deficits in motor function while cognitive function is significantly impaired in Cplx2 2/2 mice (34). Cplx2 2/2 mice have learning deficits in the Morris water maze (MWM, both acquisition and reversal) and the two-choice swim tank (reversal). The reversal learning deficits are particularly noticeable, being present from the earliest time of testing (8 weeks in the MWM), when most other behaviours are normal. Cplx2 2/2 mice also fail to develop adult patterns of exploratory behaviour in the open field and show deficits in interactive grooming behaviours (34) . Furthermore, they have selective impairments in mossy fibre (MF)-long-term potentiation (LTP) in the CA3 region of the hippocampus of Cplx2 2/2 mice (35). Synaptic plasticity, such as LTP, is a proposed neural substrate of learning and memory in the hippocampus. This impairment in MF-LTP could contribute to the spatial learning deficits observed in Cplx2 2/2 mice. 'Emotional' deficits have never been tested in Cplx2 2/2 mice, although this would be predicted since there is high expression of complexin II throughout the limbic system (30) , that has long been implicated in the mediation of emotional and social behaviours. Given that emotional/social abnormalities are common in the diseases in which complexin is dysregulated, we hypothesized that absence of complexin II in the limbic system might result in deficits in these behaviours in Cplx2 2/2 mice. During the second part of the test, when a second novel mouse (visitor 2) was introduced, the initial high level of social investigation was restored in Cplx2 +/+ mice. However, Cplx2 2/2 mice failed to investigate the novel mouse during trial 5 irrespective of the sex of the visitor mouse ( Fig. 1C and D, U ¼ 42, P , 0.0001, male visitor; U ¼ 13, P , 0.0001, female visitor). Cplx2 +/+ mice spent three times longer than Cplx2 2/2 mice interacting with a novel male mouse and twice as long interacting with a novel female mouse during trial 5. Thus, in addition to the lack of interest in a novel mouse, Cplx2 2/2 mice failed also to respond to or recognize a second novel mouse.
RESULTS

Cplx2
When treated with clorgyline, Cplx2 2/2 mice spent significantly more time (34%) investigating a novel male mouse during trial 5 (Fig. 1G , Kruskal -Wallis statistic ¼ 12.5, P , 0.01) than vehicle-treated Cplx2 2/2 mice (13%, Fig. 1E ). Furthermore, there were no significant differences between clorgyline-treated Cplx2 2/2 mice, clorgyline-treated Cplx2 +/+ mice (37%, Fig. 1G ) and vehicletreated Cplx2 +/+ mice (40%, Fig. 1E ). Similar differences were found using female visitor mice ( Fig. 1F and H, Kruskal-Wallis statistic ¼ 12.5, P , 0.01).
Clorgyline-treatment improves performance in the forced swim test in Cplx2 2/2 mice Cplx2 2/2 mice exhibit depressive behaviour in the forced swim test. Cplx2 2/2 mice were quicker to start floating than Cplx +/+ mice (U ¼ 22, P , 0.0001) and spent significantly more time floating than Cplx +/+ mice (U ¼ 2, P , 0.0001, data not shown). Both of these deficits improved with clorgyline treatment ( Fig. 2A and B (Fig. 3D , genotype, F 1,33 ¼ 12.14, P , 0.001) than Cplx +/+ mice. After clorgyline treatment, deficits improved in three out of the four aspects of locomotor and exploratory behaviours in 
2/2 mice show reductions in noradrenaline, homovanillic acid and 5-hydroxyindoleacetic acid from 2 months of age There were relatively few changes seen in the neurochemistry of Cplx2 2/2 mice. Dopamine (DA), 3,4-dihydroxyphenylacetic acid (DOPAC) and 5-hydroxytryptamine/serotonin (5-HT) levels in the hippocampus increased significantly between 2 and 8 months, but these increases were independent of genotype (P , 0.001, Table 1 ). DA and homovanillic acid (HVA) levels in the midbrain decreased significantly over the same time period, again independent of genotype (P , 0.001, Table 1 ).
However, significant reductions of noradrenaline (NA) were found in the hippocampus of Cplx2 2/2 mice compared with Cplx +/+ mice ( Table 1 , P , 0.001) from 2 months of age. HVA, a major metabolite of dopamine, was also reduced in the midbrain (P , 0.01) and 5-hydroxyindoleacetic acid (5-HIAA), the main metabolite of serotonin, was reduced in the hippocampus and midbrain (P , 0.001 for both regions). No differences in any measurements were found in the stria- (Fig. 5C and D, 127 + 2%, n ¼ 6; F 4,47 ¼ 84.3, P , 0.0001). In the combined presence of elevated Ca 2+ (5 mM) and isoprenaline (1 mM), MF-LTP in Cplx2 2/2 mice was completely restored to control levels ( Fig. 5E and F, 208 + 12%, n ¼ 5; F 2,37 ¼ 127.4, P , 0.0001).
DISCUSSION
We have shown previously that although Cplx2 2/2 mice appear outwardly normal, they exhibit progressive deficits in motor and cognitive behaviours from an early age, with the precise age of onset dependent upon the particular test (34) . In addition, they have abnormalities in synaptic plasticity that might contribute to these deficits (35) . Here we show that Cplx2 2/2 mice also have significant deficits in social recognition and social interactions, and they show depressive-like behaviours. Pharmacological treatment with clorgyline reverses multiple aspects of the abnormal phenotype in 
Significant results are shown in bold. Fig. S3 ), suggesting that there are no major deficits in hearing or olfactory discrimination. Therefore, we suggest that the deficits reported here were not mediated by the changes in sensory function although we cannot rule out a contribution from sensory impairment.
Clorgyline treatment reversed the decrease in levels of NA found in the hippocampus. Clorgyline is an irreversible inhibitor of monoamine oxidase (MAO) that was developed originally as an antidepressant but is no longer used in humans. It increases NA levels, although its effects are not selective and it also increases the levels of serotonin, adrenaline and dopamine. There is evidence to suggest that restoration of NA levels by clorgyline may underlie the improvements in behaviour seen here in Cplx2 2/2 mice. First, in the forced swim test, it has been shown that climbing/escape swimming behaviour was increased by antidepressant drugs with NA selective effects whereas horizontal swimming behaviour was increased by selective serotonin reuptake inhibitors (SSRIs, 5-HT dependent; 37). Here, clorgyline-treated Cplx2 2/2 mice spent more time engaged in climbing/escape swimming behaviours than vehicle-treated Cplx2 2/2 mice, whereas there was no difference in horizontal swimming behaviour (5-HT dependent) between any of the groups. It is possible that the increase in swimming behaviour observed was a result of a general increase in locomotor activity caused by the drug rather than by its 'antidepressant' action. However, we have shown previously that swimming style and strength is normal in Cplx2 2/2 mice, and furthermore that there was no significant differences in swimspeed between Cplx2 2/2 mice and WT controls at 1 year in the MWM (34) . Therefore, we conclude that this specific increase in climbing/escape swimming behaviour suggests that the improvements were mediated by the antidepressant action of the drug rather than a general increase in locomotor activity. Secondly, activity is proportional to concentrations of NA. There is evidence that an increased investigative activity and a decreased emotionality in a novel environment are seen in animals with higher levels of NA synthesis and a decreased density of adrenergic receptors in the brain (38) . Here, we show that Cplx2 2/2 mice exhibit their most profound deficits in motor and exploratory behaviour in the LABORAS during the first light period when the mice are habituating to a novel environment. Of particular interest is that clorgyline treatment reversed these deficits during this time period in Cplx2 2/2 mice. Note that although we used clorgyline for our study, this would not be suitable for use in humans. Side effects (in particular, the 'cheese effect') have limited the use of irreversible MAO inhibitors as therapeutic agents (39) . These deleterious side effects can now be avoided by using reversible MAOA inhibitors such as moclobemide and lazabemide or other new generation antidepressant agents (39) .
We were able to reverse the selective deficit seen in LTP in Cplx2 2/2 mice using isoprenaline. Isoprenaline is a b 1 -and b 2 -adrenoceptor agonist and as such mimics the action of NA. It is possible that NA reduction may underlie the LTP deficit in Cplx2 2/2 mice. Noradrenergic enhancement of LTP in mossy fibre synapses in the hippocampus has been shown previously (40) (41) (42) . Activity-dependent alterations in synaptic efficacy (synaptic plasticity), such as LTP and long-term depression (LTD), are widely believed to underlie information processing and storage in the brain (43) . Reduced plasticity is evident in the hippocampus of Cplx2 2/2 mice weeks before the first signs of an overt phenotype in Cplx2 2/2 mice, thus supporting the suggestion that altered synaptic plasticity contributes to the cognitive dysfunction seen in these mice particularly in the early stages of their phenotype. It would be interesting to investigate whether clorgyline treatment would also reverse the deficits in learning and memory in the MWM that are seen in Cplx2 2/2 mice, since the MWM is a task commonly used to test spatial memory, and accurate performance depends on intact hippocampal function (44). 
Significant results are shown in bold.
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There is a growing body of evidence to support the idea that disturbed synaptic transmission contributes to the pathophysiology of mood disorders (45) (46) (47) (48) , although it is not clear whether dysregulated complexin expression plays a causal role or whether it contributes solely to the symptomatology (reviewed by 49). Post-mortem studies have reported reduced complexin expression levels in bipolar disorder and major depression (11 -14) and in an animal model of depression (24) . Zink et al. (50) have also shown that antidepressant treatment with desipramine (reuptake inhibitor of NA) and tranylcypromine (MAOA/B inhibitor) increases Cplx2 mRNA expression in WT mice, whereas fluoxetine (SSRI) had no effect on Cplx2 expression (although it did increase Cplx1 expression).
Here, we found significant reductions of NA in the hippocampus of Cplx2 2/2 mice that were reversed after clorgyline treatment. We did not measure mRNA expression, although based on the findings of Zink et al. it seems likely that upregulation of complexin as a result of selective enhancement of NA might facilitate SNARE complex function and synaptic transmission at the synapse (50) .
The phenotype of the Cplx2 2/2 mouse recapitulates many of the subtle aspects or endophenotypes of neurological disease (e.g. deficits in cognitive and social behaviour, depression and subtle motor abnormalities). Here we have shown that pharmacological treatment with clorgyline can reverse deficits in neurochemistry, behaviour and electrophysiology in Cplx2 2/2 mice. These data support the idea that Cplx2 is an attractive candidate gene involved in the fundamental processes of affective disorders and as such an important possible target for antidepressive therapy.
MATERIALS AND METHODS
Animals
Cplx2 mice were generated by homologous recombination in embryonic stem cells (3) . All mice used in this study were F1 or F2 mice bred from founders with a mixed genetic background (129Ola/C57Bl6) and were taken from a colony established in the Department of Pharmacology, University of Cambridge. Cplx2 2/2 mice have now been backcrossed onto a C57/Bl6 inbred background for 10 generations, but no change in their overt or measured phenotype has been observed (data not shown). Mice were housed and husbandry maintained as described previously (34) . In addition, all mice had an environment enriched by the presence of a red Perspex igloo (Datesand, Manchester, UK) in their home cage. All experimental procedures were licensed and undertaken in accordance with the regulations of the UK Animals (Scientific Procedures) Act 1986.
Drug treatment
All mice were dosed daily by intraperitoneal (ip) injection with either clorgyline (Sigma, UK) or vehicle (0.9% saline). Clorgyline was administered at a dose of 1.5 mg/kg. Mice were treated for at least 21 days prior to post-drug behavioural testing and treatment continued until the end of the experiment. Specific details (ages, genotypes and group sizes) of mice used are detailed below.
Social recognition
Social interactions (recognition and memory) were measured in a test described by Ferguson et al. (51) . The task is based on the natural tendency of WT mice to investigate another mouse that is introduced to its home cage. When the same 'visitor' mouse is presented repeatedly, the response of the resident mouse declines to a low level. If a new 'visitor' mouse is then presented, the initial level of social investigation is typically reinstated. Both juvenile male and female mice were used as 'visitor' mice. Briefly, a 'resident' mouse was placed in a clean cage and allowed habituate for 10 min, after which an unfamiliar mouse (visitor 1) was introduced into the cage. After 1 min, visitor 1 was removed, placed in a holding cage and then reintroduced to the resident mouse for a further three 1-min trials at 10 min inter-trial intervals. In the fifth trial, a different unfamiliar mouse (visitor 2) was introduced into the cage. The time the resident mouse spent interacting with each visitor mouse was recorded. Mice were tested at 4 months of age (16 Cplx +/+ , 19 Cplx2 2/2 ). These mice were then randomly assigned to either drug (8 Cplx +/+ , 9 Cplx2 2/2 ) or vehicle (8 Cplx +/+ , 10 Cplx2 2/2 ) groups, and retested after 4 weeks clorgyline treatment.
Forced swim test
Depressive behaviour was tested in the forced swim test, a standard animal test of depression used to demonstrate the efficacy of antidepressants (52) . Each mouse was placed into water 22 cm deep at ambient temperature (21 + 18C) in a 5 l Pyrex beaker for 7 min. The following parameters were measured: the latency to float (after the first 30 s); the duration of immobility time (after the first 120 s, measured when the mouse floated in the water in an upright position, making only slight movements to keep its head above the surface); climbing behaviour (upward directed movements of the forepaws); horizontal swimming behaviour. Cplx2 mice were tested at 1 year (18 Cplx +/+ , 16 Cplx2 2/2 ) and were then randomly assigned to either drug (9 Cplx +/+ , 7 Cplx2 2/2 ) or vehicle (9 Cplx +/+ , 9 Cplx2 2/2 ) groups, and retested after 3 weeks clorgyline treatment.
Motor activity
The LABORAS (Metris b.v., The Netherlands) was used to measure motor activity and exploration (53, 54) . Mice were singly housed with ad libitum access to food and water and monitored for 23.5 h. Mice were tested at 4 months (16 Cplx +/+ , 19 Cplx2 2/2 ), after which they were randomly assigned to either drug (8 Cplx +/+ , 9 Cplx2 2/2 ) or vehicle (8 Cplx +/+ , 10 Cplx2 2/2 ) groups, and retested in the LABORAS after 5 weeks clorgyline treatment.
Neurochemistry
Neurochemical measurements were made from five different brain regions (hippocampus, frontal cortex, striatum, cerebellum and midbrain) using high-performance liquid chromatography. NA, DA, DOPAC, HVA, 5-HIAA and 5-HT were measured in all regions. Brain tissue was homogenized and proteins precipitated in 0.1 M perchloric acid and 0.1 mM ascorbic acid. Supernatants were then injected onto a Hypersil 5 mm ODS C18 (150 × 4.6 mm) column and analysed by electrochemical detection. The mobile phase (pH 3.0) consisted of 0.1 M phosphate buffer containing 2.5 mM octane sulphonate, 0.5 mM ethylenediaminetetraacetic acid (EDTA), 20.5 ml acetic acid and 12% methanol, at a flow rate of 1 ml/min. Neurochemical measurements were taken from three different groups of mice; 2 months (8 Cplx2 
Electrophysiology
Experiments were carried out as described in Gibson et al. (35) . Briefly, hippocampal slices prepared from 4-to 10-week-old male Cplx +/+ and Cplx2 2/2 mice were perfused with artificial cerebrospinal fluid (26 -288C) containing the g-aminobutyric acid type A (GABA A )-receptor antagonist, picrotoxin (50 mM) . Electrical stimulation at the dentate gyrus granule cell/hilus border evoked MF field excitatory postsynaptic potentials (EPSPs) in stratum lucidum of CA3 (paired pulse ratio . 1.6 and frequency-dependent facilitation; 
Statistical analysis
Most behavioural data were subjected to analysis of variance (ANOVA), with one or two between-subject factors (genotype, treatment) with repeated measures. Where applicable, Bonferroni's post hoc tests were used. For data that were not normally distributed, the Kruskal-Wallis test with Dunnet's post hoc test was used. An unpaired two-tailed t-test (or a Mann -Whitney two-tailed test in the case of non-parametric data) was applied to test the significance of differences between mean values where factorial ANOVA was not required. Statistical analyses were performed using GraphPad Prism (Version 4.0, USA) and Statistica (Version 9.0, StatSoft, Inc., USA). A critical value for significance of P , 0.05 was used throughout the study.
